Posts

Showing posts with the label Anaplastic Astrocytoma market

Anaplastic Astrocytoma - Pharmaceuticals and Healthcare

Image
Latest Pharmaceutical and Healthcare disease pipeline guide  Anaplastic Astrocytoma    - Pipeline Review, H2 2017, provides an overview of the  Anaplastic astrocytoma (Oncology) pipeline landscape. Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include a headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation. ...